Clinical studies have demonstrated that SGLT2 inhibitors also downregulate PTGDS-containing protein complexes (among 19 targets) and mitigate TGF-β-induced epithelial-mesenchymal transition in diabetic nephropathy (Ahluwalia et al., 2023). Here, TGFB1 is linked to diabetic kidney disease.